PO.2.35 Association between clinical manifestations and SLE-specific antibodies measured by a novel pmat technology in systemic lupus erythematosus. (27th September 2022)

• Record Type: Journal Article
• Authors: Seaman, A; Andalucia, C; López-Hoyos, M; Irure-Ventura, J; González-López, E; Roa-Bautista, A; Aron, E; Aure, MA; Mahler, M
• Is Part Of: Lupus science & medicine. Volume 9(2022)Supplement 2
• Page Start: A41
• Page End: A42
• Publication Date: 2022-09-27
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2022-elm2022.65
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Purpose: Systemic Lupus Erythematosus (SLE) patients can present a wide range of signs and symptoms, being arthritis, malar rash, fever, photosensitivity, nephropathy, neurological involvement, thrombocytopenia, thrombosis, lymphadenopathy some of the most common ones. The 2019 EULAR/ACR classification criteria for systemic Lupus Erythematosus (SLE) includes the presence of anti-Sm antibodies, anti-dsDNA antibodies. Anti-dsDNA, anti-Sm and anti-Ribo-P antibodies are highly specific for SLE and depending on the assay used can correlate with some clinical manifestations. This study aimed to evaluate the association of anti-dsDNA, anti-Sm and anti-Ribo-P autoantibodies with clinical features (renal articular, skin, ocular, neurological, cardiac and hematological manifestations) in a Spanish SLE cohort. Methods: A total of 292 SLE patients were tested for anti-dsDNA, anti-Sm and anti-Ribo-P antibodies by the novel PMAT (research use only) (Inova Diagnostics, USA). The associations between anti-dsDNA, anti-Sm and anti-Ribo-P autoantibodies and clinical features (renal, articular, skin, ocular, neurological, cardiac and hematological manifestations) were assessed using Fisher´s exact test. Results: Of the 292 SLE samples, 32.9% (n=96) were positive for a single analyte (30.5% (n=89) were positive for Aptiva anti-dsDNA only, 1.7% (n=5) were positive for Aptiva anti-Sm only, and 0.7% (n=2) were positive for Aptiva anti-Ribo-P only). In addition, 2.7% (n=8) were positive for all three analytes and 7.5% (n=22) were positive for a combination of two analytes ( Figure 1 ). There were significant associations between anti-dsDNA autoantibodies and renal involvement (p=0.0007) and between anti-Sm autoantibodies and neurological manifestations (p=0.0091). Sixty-three percent of SLE patients with renal involvement were positive for at least one of the SLE-specific autoantibodies ( Figure 2 ) compared to thirty-eight percent of SLE patients without renal involvement ( Figure 3 ). Conclusion: A strong association was observed between anti-dsDNA antibodies measured using Aptiva dsDNA PMAT and renal involvement and between anti-Sm antibodies and neurological manifestations. The presence of anti-dsDNA, anti-Sm and anti-Ribo-P autoantibodies were higher in patient with renal involvement.